Oncology
PSMA+ mCRPC
Conference Reporter® Podcast: Terminology and Clinical Trial Innovation in Positron Emission Tomography–Defined Advanced Prostate Cancer
The field of advanced prostate cancer is rapidly evolving, driving new terminology and study benchmarks. The Prostate Cancer Working Group 4 has proposed a framework that more precisely accounts for prior treatment exposure and introduces novel prostate-specific membrane antigen positron emission tomography–based progression criteria. These efforts aim to harmonize end points, improve prognostication, and modernize clinical trial design, as discussed in today’s podcast from the 2026 ASCO Annual Meeting.
Following these presentations, featured expert Andrew J. Armstrong, MD, MSc, was interviewed by Conference Reporter Editor-in-Chief Tom Iarocci, MD. Clinical perspectives from Dr Armstrong on these findings are presented here.
Armstrong AJ, Azad AA, Iguchi T, et al. Radiographic progression with and without prostate-specific antigen rise in patients with advanced prostate cancer treated with enzalutamide. J Clin Oncol. 2026;44(14):1309-1322. doi:10.1200/JCO-24-02829
Armstrong AJ, Morris MJ, Abida W, et al; PCWG4 Writing Group. Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4. J Clin Oncol. 2026;44(13):1249-1265. doi:10.1200/JCO-25-02834
Azad AA, Agarwal N, Armstrong AJ, et al. Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01. Future Oncol. 2026;22(10):1153-1163. doi:10.1080/14796694.2026.2655433c
Dorff TB, Peer A, Sharma MR, et al. A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract 5014] [session: Genitourinary cancer—prostate, testicular, and penile]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Emmett L, Sathekge MM, Crumbaker MA, et al. AcTION: phase 1 study of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) in men with metastatic castration-resistant prostate cancer (mCRPC) with or without prior [177Lu]Lu-PSMA (177Lu-PSMA) radioligand therapy (RLT) [abstract 5010] [session: Radiation re-imagined: radioligand innovation in prostate cancer]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Morris MJ, George DJ, Gupta S, et al. CONVERGE-01 part 3: Ac-225 rosopatamab tetraxetan (CONV01-α) in Lu-PSMA-pretreated metastatic castration-resistant prostate cancer (mCRPC) [abstract 5011] [session: Radiation re-imagined: radioligand innovation in prostate cancer]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Morris MJ, Wong JYC, Nordquist L, et al. A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac)-labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42(suppl 16):5010. doi:10.1200/JCO.2024.42.16_suppl.5010
Sathekge MM, Mugisha J, Kabunda J, et al. AKY-2519, a novel B7-H3-targeted radioconjugate, and its biodistribution profile in patients with mCRPC [abstract 3097] [session: Developmental therapeutics—molecularly targeted agents and tumor biology]. Poster presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Zanvit P, van Dyk D, Fazenbaker C, et al. Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. J Clin Invest. 2023;133(22):e169655. doi:10.1172/JCI169655
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.
